Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGLE NASDAQ:CERC NASDAQ:EVLO NASDAQ:MNOV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGLEAeglea BioTherapeutics$11.47$2.66▼$32.75$48.64M2.5795,409 shs43,300 shsCERCCerecor$13.95-6.8%$2.60$1.98▼$4.50$1.34B1.441.27 million shs244,495 shsEVLOEvelo Biosciences$0.00$0.00$0.00▼$0.00$4K0.928,557 shs1,000 shsMNOVMediciNova$1.24-1.6%$1.29$1.13▼$2.55N/A0.4426,070 shs10,790 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGLEAeglea BioTherapeutics0.00%0.00%0.00%0.00%0.00%CERCCerecor0.00%+4.10%+28.22%+191.84%+46.23%EVLOEvelo Biosciences0.00%-60.00%-60.00%-60.00%+100.00%MNOVMediciNova0.00%-1.56%+2.44%-1.56%-29.21%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGLEAeglea BioTherapeutics$11.47$2.66▼$32.75$48.64M2.5795,409 shs43,300 shsCERCCerecor$13.95-6.8%$2.60$1.98▼$4.50$1.34B1.441.27 million shs244,495 shsEVLOEvelo Biosciences$0.00$0.00$0.00▼$0.00$4K0.928,557 shs1,000 shsMNOVMediciNova$1.24-1.6%$1.29$1.13▼$2.55N/A0.4426,070 shs10,790 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGLEAeglea BioTherapeutics0.00%0.00%0.00%0.00%0.00%CERCCerecor0.00%+4.10%+28.22%+191.84%+46.23%EVLOEvelo Biosciences0.00%-60.00%-60.00%-60.00%+100.00%MNOVMediciNova0.00%-1.56%+2.44%-1.56%-29.21%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGLEAeglea BioTherapeutics 0.00N/AN/AN/ACERCCerecor 0.00N/AN/AN/AEVLOEvelo Biosciences 0.00N/AN/AN/AMNOVMediciNova 2.50Moderate Buy$7.00464.52% UpsideCurrent Analyst Ratings BreakdownLatest MNOV, EVLO, CERC, and AGLE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025MNOVMediciNovaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/22/2025MNOVMediciNovaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.009/11/2025MNOVMediciNovaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/27/2025MNOVMediciNovaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.007/24/2025MNOVMediciNovaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.00(Data available from 10/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGLEAeglea BioTherapeutics$2.33M0.00N/AN/A($60.61) per share0.00CERCCerecor$6.70M199.90N/AN/A$0.22 per share63.41EVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AMNOVMediciNova$1MN/AN/AN/A$1.07 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGLEAeglea BioTherapeutics-$83.82M-$75.59N/AN/AN/A-22,195.36%-132.05%-146.87%N/ACERCCerecor-$63.50M-$0.57N/AN/AN/A-1,194.82%-261.82%-133.96%N/AEVLOEvelo Biosciences-$114.53MN/A0.00∞N/AN/AN/AN/A11/24/2025 (Estimated)MNOVMediciNova-$11.04M-$0.25N/AN/AN/AN/A-23.12%-21.85%11/12/2025 (Estimated)Latest MNOV, EVLO, CERC, and AGLE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025MNOVMediciNova-$0.07-$0.07N/A-$0.07N/A$0.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGLEAeglea BioTherapeuticsN/AN/AN/AN/AN/ACERCCerecorN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/AMNOVMediciNovaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGLEAeglea BioTherapeuticsN/A4.594.59CERCCerecor0.792.192.18EVLOEvelo BiosciencesN/AN/AN/AMNOVMediciNovaN/A13.2613.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGLEAeglea BioTherapeuticsN/ACERCCerecor62.84%EVLOEvelo Biosciences0.31%MNOVMediciNova9.90%Insider OwnershipCompanyInsider OwnershipAGLEAeglea BioTherapeutics6.60%CERCCerecor45.70%EVLOEvelo Biosciences1.02%MNOVMediciNova13.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGLEAeglea BioTherapeutics694.05 million3.78 millionOptionableCERCCerecor3196.01 millionN/ANot OptionableEVLOEvelo Biosciences12018.98 million18.79 millionNo DataMNOVMediciNova10N/AN/AOptionableMNOV, EVLO, CERC, and AGLE HeadlinesRecent News About These CompaniesMediciNova, Inc. to Present Corporate Overview at LD Micro Main Event XIX Investor ConferenceOctober 6, 2025 | quiverquant.comQMediciNova to Present at the LD Micro Main Event XIX Investor ConferenceOctober 6, 2025 | globenewswire.comMediciNova completes patient enrollment in COMBAT-ALS Phase 2b/3 trialSeptember 22, 2025 | msn.comMediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)September 22, 2025 | finance.yahoo.comMediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MNDSeptember 16, 2025 | markets.businessinsider.comMediciNova provides update on SEPA, COMBAT-ALS trial enrollmentSeptember 9, 2025 | msn.comMediciNova, Inc. Announces $30 Million Standby Equity Purchase Agreement and Reports Clinical Trial Enrollment SuccessSeptember 8, 2025 | quiverquant.comQMediciNova Provides Shareholder Update on Key DevelopmentsSeptember 8, 2025 | globenewswire.comMediciNova to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | markets.businessinsider.comMediciNova to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | globenewswire.comMediciNova, Inc. Achieves Enrollment Target for COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 for ALS TreatmentAugust 26, 2025 | quiverquant.comQMediciNova Achieves Enrollment in COMBAT-ALS Clinical TrialAugust 26, 2025 | globenewswire.comMediciNova files to sell 25M shares of common stock for holdersAugust 22, 2025 | msn.comMediciNova: Q2 Earnings SnapshotAugust 14, 2025 | sfgate.comMediciNova signs standby equity purchase agreement for up to $30MAugust 1, 2025 | msn.comMediciNova Secures $30 Million Equity Purchase AgreementAugust 1, 2025 | tipranks.comMediciNova, Inc. Announces Standby Equity Purchase Agreement for Up to $30 Million in Common StockJuly 31, 2025 | quiverquant.comQMediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 MillionJuly 31, 2025 | globenewswire.comMediciNova, Inc.: MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical TrialsJuly 24, 2025 | finanznachrichten.deMediciNova, Inc. Reports Progress in Enrollment for Clinical Trials of MN-166 and MN-001July 24, 2025 | quiverquant.comQMedia Sentiment Over TimeMNOV, EVLO, CERC, and AGLE Company DescriptionsAeglea BioTherapeutics NASDAQ:AGLEAeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.Cerecor NASDAQ:CERCCerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.Evelo Biosciences NASDAQ:EVLO$0.0002 0.00 (0.00%) As of 03:46 PM EasternEvelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.MediciNova NASDAQ:MNOV$1.24 -0.02 (-1.59%) Closing price 04:00 PM EasternExtended Trading$1.24 0.00 (-0.40%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Applied Digital’s Shorts Got Squeezed—Now What? Levi Strauss Stock Set to Reach New Highs in 2026 Alphabet: The AI Powerhouse Driving Markets Into 2026 Is the Reddit-ChatGPT Love Affair Over? Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
